Physician profile
Mark A Silverman
NPI 1548227465
$3,018.01
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $542 · 2020: $461 · 2021: $752 · 2022: $439 · 2023: $393 · 2024: $430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $823.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $823.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $375.12 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $366.43 | 2019-2024 | Xifaxan |
| Abbvie INC. | $324.52 | 2019-2024 | |
| Glaxosmithkline, LLC. | $286.31 | 2021-2023 | Shingrix, Arexvy |
| Qol Medical, LLC | $281.83 | 2020-2024 | Sucraid, Sucraid |
| Novo Nordisk INC | $136.39 | 2021-2024 | Ozempic, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $120.81 | 2020-2024 | Entyvio, Vpriv |
| Merck Sharp & Dohme LLC | $111.96 | 2020-2024 | Gardasil, Gardasil 9 |
| Janssen Biotech, INC. | $86.02 | 2022-2024 | Simponi, Remicade, Stelara |
| Braintree Laboratories, INC. | $84.72 | 2019-2024 | Sutab, Suflave |
| Celgene Corporation | $81.61 | 2023-2024 | Zeposia |
| Ferring Pharmaceuticals INC. | $78.30 | 2020-2022 | |
| Daiichi Sankyo INC. | $64.09 | 2022-2024 | Injectafer |
| Redhill Biopharma INC. | $62.64 | 2021-2022 | |
| Shire North American Group INC | $60.85 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $59.15 | 2019-2021 | |
| Pfizer INC. | $56.82 | 2023-2024 | |
| Astrazeneca Pharmaceuticals Lp | $46.99 | 2024 | Airsupra |
| Phathom Pharmaceuticals, INC. | $44.65 | 2023-2024 | Voquezna |
| Alfasigma USA, INC. | $37.19 | 2020 | |
| Glycomark, INC. | $31.04 | 2019 | |
| Dermavant Sciences, INC. | $22.73 | 2023 | Vtama |
| Ironwood Pharmaceuticals, INC | $21.80 | 2020 | |
| Alnylam Pharmaceuticals INC. | $21.11 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.47 | 2021 | |
| Exact Sciences Corporation | $19.29 | 2023 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $19.04 | 2020 | |
| Celltrion USA INC. | $18.66 | 2024 | Vegzelma |
| Lilly USA, LLC | $18.18 | 2023 | Mounjaro |
| Shield Therapeutics INC | $16.71 | 2024 | |
| Intra-Sana Laboratories | $16.60 | 2021 | |
| Gilead Sciences, INC. | $13.15 | 2019 | |
| Linus Health, INC. | $12.83 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Silverman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.